



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Oversight Committee Meeting Minutes
May 17, 2023

NOTE: Unless the information is confidential, the reports, presentations, and grant award information referenced in the minutes are available at <http://ocmeetings.cprit.texas.gov> in the “Oversight Committee Board Packet” section for the corresponding meeting date.

Call to Order – Agenda Item 1

Presiding Officer Dr. Mahendra Patel announced a quorum present and called the meeting to order at 9:00 a.m.

Roll Call/Excused Absences – Agenda Item 2

Committee Members Present

Mahendra Patel, M.D., P.A.
David Cummings, M.D.
Donald (Dee) Margo
Ambrosio Hernandez, M.D.
Will Montgomery
Cindy Barberio Payne
Bill Rice, M.D.
Craig Rosenfeld, M.D.

**Adoption of Minutes from the February 15, 2023, Meeting – Agenda Item 3,
Tab 1**

MOTION:

On a motion by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee voted unanimously to approve the minutes of the February 15, 2023, Oversight Committee meeting as presented.

Public Comment – Agenda Item 4

Presiding Officer Dr. Patel noted for the record that no member of the public requested to provide comments.

Chief Executive Officer Report – Agenda Item 5, Tab 2

Presiding Officer Dr. Patel recognized Chief Executive Officer Wayne Roberts to present his report. Mr. Roberts introduced Chief Strategic Initiatives and Intellectual Property Officer Tracey Davies. Ms. Davies gave a status update on the intellectual property database project. She expects to complete a contract with a third-party vendor by mid-summer.

An Oversight Committee member asked if the information would be searchable on the internet. Ms. Davies responded that there is not an answer to that question yet; however, the software can make non-confidential information searchable.

An Oversight Committee member asked if the information is available by a request for information under the Texas Public Information Act. Ms. Davies responded that non-confidential information is available. If CPRIT receives a request for confidential information, the agency would assert applicable exceptions to production available under the Texas Public Information Act.

An Oversight Committee member asked about the need for the database. Ms. Davies responded that the database would allow CPRIT to have a more comprehensive view of the patents resulting from CPRIT funded IP and that this information may improve the ability to track revenue generated and stimulate further development.

An Oversight Committee member asked about IP ownership related to product development research. Ms. Davies responded that CPRIT has revenue sharing terms with each grantee, but CPRIT does not own the IP generated by the grantee's research.

Oversight Committee members thanked Ms. Davies for her work on the IP database project.

Mr. Roberts proceeded with his Chief Executive Officer report with an update on agency funds available and introduced new personnel. He provided a brief legislative update, reporting that there should not be any surprises in the state budget related to CPRIT and the committees included the 5 percent per year cost-of-living exempt salary adjustment to the chief scientific officer position but not the one for the chief executive officer.

Chief Compliance Officer Report and Compliance Certification for the Proposed Grant Awards – Agenda Item 6, Tab 3

Presiding Officer Dr. Patel recognized Chief Compliance Officer Vince Burgess and Program Manager Stephen Nance to present the Compliance Report and Compliance Certification of Grant Award Process.

Mr. Nance presented the Compliance Report for the past quarter's activities. There were no questions for Mr. Nance

Following Mr. Nance's report, Mr. Burgess presented the Compliance Certification for the proposed academic research and Product Development grant awards, confirming that the proposed awards and review process complied with all applicable state and agency requirements.

Chief Scientific Officer Report and Grant Award Recommendations – Agenda Item 7, Tab 4

Presiding Officer Dr. Patel recognized Dr. Le Beau to provide the Academic Research Program update and introduce the Program Integration Committee’s Grant Award recommendations.

Dr. Le Beau directed Oversight Committee members to Table 1 on page 4 of the Proposed Grant Awards Book that displayed the Scientific Review Council (SRC) and Program Integration Committee (PIC) recommendations for the FY 2023 Recruitment, Cycle 23.4, including three awards from two grant mechanisms totaling \$14,000,000.

Dr. Le Beau provided an overview of the recommended awards.

Rank	ID	Mechanism	Score	Application Title	Candidate	Organization	Budget
1	RR230031	RFTFM	1.0	Nomination of Dian Yang, Ph.D. for a CPRIT Recruitment of a First-Time Tenure-Track Faculty Member Award Investigator	Dian Yang, Ph.D.	The University of Texas Southwestern Medical Center	\$2,000,000
2	RR230032	REI	1.8	Nomination of Yuan Zhu, Ph.D. for a CPRIT Recruitment of an Established Investigator Award	Yuan Zhu, Ph.D.	The University of Texas Southwestern Medical Center	\$6,000,000
3	RR230029	REI	2.0	Recruitment of Established Investigators - Dr. King	Michael King, Ph.D.	Rice University	\$6,000,000

REI: Recruitment of Established Investigator

RFTFM: Recruitment of First-Time, Tenure Track Faculty Members

Following the award recommendation presentation, Dr. Le Beau provided a program update, including the second cycle of applications for FY 2023 and the open request for applications for FY 2024 awards. She also introduced three proposed FY 2024 requests for applications for Oversight Committee approval.

An Oversight Committee member congratulated Dr. Le Beau for the collaborative research noted between the approved recruitment applicants and TREC eligible institutions.

Compliance Certification

Presiding Officer Dr. Patel reminded members that Mr. Burgess previously certified compliance of the academic research awards process.

Conflict of Interest Notification

Presiding Officer Dr. Patel noted for the record that no Oversight Committee member reported a conflict of interest with any award academic research recommendation presented.

Approval Process – Academic Research Awards

MOTION:

On a motion made by Mr. Margo and seconded by Dr. Rice, the Oversight Committee members voted unanimously to approve the PIC's recommendations for one Recruitment of First-Time, Tenure-Track Faculty Members award and two Recruitment of Established Investigators awards.

MOTION:

On a motion made by Dr. Hernandez and seconded by Mr. Margo, the Oversight Committee members voted unanimously to approve the delegation of contract negotiation authority to CPRIT's CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

Approval For Proposed Fiscal Year 2024 RFAs

MOTION:

On a motion made by Mr. Margo and seconded by Mr. Montgomery, the Oversight Committee members voted unanimously to approve the three proposed FY 2024 RFAs presented by Dr. Le Beau.

Chief Prevention Officer Report – Agenda Item 8, Tab 5

Presiding Officer Dr. Patel recognized Chief Prevention Officer Ramona Magid to present the prevention program update. Ms. Magid reported on activities related to the applications for the second cycle FY 2023 Cycle 2 and the newly released request for applications for FY 2024.

Lastly, Ms. Magid also reported that Mr. Carlton Allen, Program Manager for Prevention, is leading the revision of the *Texas Cancer Plan* and has begun meeting with multiple stakeholders to gather input.

In response to a question by an Oversight Committee member regarding the time necessary to solicit and approve prevention grants, Ms. Magid explained that timelines for the two prevention cycles each year have not changed.

An Oversight Committee member asked whether prevention grantees were reporting fewer cancer screenings and later stage cancer diagnoses. Ms. Magid responded that grantees had not reported major disruptions and that screening levels had returned to pre-pandemic levels.

An Oversight Committee member inquired about the expected publication date for the updated *Texas Cancer Plan* and whether it would be ready by CPRIT's conference. Ms. Magid clarified that the anticipated release date is June 2024 according to the schedule she developed based upon the 2012 and 2018 revisions. She explained the lengthy update and data-gathering process in more detail, including the need for significant input from many stakeholders, as well as the Department of State Health Services and its Texas Comprehensive Cancer Control Program, and work necessary for charting new goals.

In response to a question from an Oversight Committee member about whether CPRIT has prevention projects in all counties, Ms. Magid reported that CPRIT prevention projects are currently serving every Texas county.

An Oversight Committee member asked whether CPRIT had heard about insurance companies possibly increasing their co-pays for colonoscopies, Ms. Magid responded that no grantees have reported this issue. She explained that CPRIT-funded programs may use grant funds to cover co-pays.

Chief Product Development Officer Report – Agenda Item 9, Tab 6

Presiding Officer Dr. Patel recognized Chief Product Development Officer Dr. Ken Smith to present the Product Development Research update.

Dr. Smith presented the proposed product development grant awards.

FY 2023 Cycle 1 Award Recommendations

Rank	ID	RFA	Company	Project	Score	Budget
1	DP230079	TNTC FULL	Resilience Texas, LLC dba CTMC	Building Differentiated Cell Therapy Manufacturing Technologies to Attract Value-Added Biotech Partnerships	2.3	\$9,100,000
2	DP230062	TTC FULL	7 Hills Pharma LLC	7HP349, a Small Molecule, Oral Integrin Activator to Treat Patients With anti-PD-1 Resistant Melanoma	2.6	\$13,439,001
3	DP230064	SEED Ther.	OmniNano Pharmaceuticals LLC	IND-Enabling Studies of ONP-001: A Nano-Codelivery Formulation with Two Drugs of Distinct Mechanisms of Action for Treating Pancreatic Ductal Adenocarcinoma	3.3	\$2,711,437
4	DP230076	TTC FULL	OncoResponse	OncoResponse OR502 anti-LILRB2 monoclonal antibody Phase 1-2 clinical study	3.6	\$13,259,174
5	DP230066	TTC FULL	Pulmotect, Inc.	Improving Cancer Patient Outcomes by Activating Lung Innate Immunity Lutetium-177 for Use in Prostate Cancer Therapy	3.3	\$8,851,165
6	DP230071	TTC FULL	Allterum Therapeutics, LLC	Clinical development of a novel CD127 antibody for treating patients with relapsed/refractory Acute Lymphoblastic Leukemia (ALL)	2.6	\$11,721,150
TOTAL						\$ 59,081,927

TNTC – Texas New Technologies Company
TTC – Texas Therapeutics Company
SEED – Seed Company

He explained that each of the six companies recommended for awards worked with him to

reduce their proposed budgets to accommodate funding all projects recommended by the Product Development Review Council.

An Oversight Committee member asked Dr. Smith whether CPRIT guaranteed the company's remaining budget for goals and objectives that CPRIT cut during the budget negotiations. Dr. Smith responded that this was not the case.

Dr. Smith explained that the recommended companies reduced their requested budgets by approximately 30% in response to another member's question.

An Oversight Committee inquired whether Dr. Smith thought negotiating budgets before final award approval was a good exercise to use moving forward. Dr. Smith responded that he would continue this process as long as it works towards reasonable budgets so the program may fund more companies.

Another Oversight Committee member asked about the review committee's involvement in the budget negotiation process. Dr. Smith explained that the program conducts the negotiations after the review committee establishes contingencies for the project. CPRIT brings in a third-party due diligence and a clinical consulting firm to assist with budget review. Mr. Roberts added that CPRIT previously managed the contracting and budget negotiation process after OC approval. Ms. Doyle explained that the time invested negotiating the budgets prior to final approval will expedite the contract execution process.

When asked by an Oversight Committee member about whether he thought that applicants for grants may inflate the project budget because they know that the agency will cut the proposal, Dr. Smith responded that some companies may do so, but not all. Ms. Doyle added that the requirement of matching funds does discourage companies from inflating their budgets because they must provide a match for their budget request.

An Oversight Committee member asked if the Academic research program was considering pre-approval budget negotiations. Mr. Roberts responded that all staff have used this process before, and the academic research program has recently discussed the topic. He clarified that the other two programs do not initiate the budget reductions at this level of detail since the three CPRIT programs are different.

Referring to the Product Development Advisory Committee report included in the packet, an Oversight Committee member expressed concerns regarding the number of full applications that went through peer review in the FY 2023 cycle. The PDAC report mentioned applicants may race to apply in FY 2024. Dr. Smith explained that the request for applications for the FY 2024 product development applications notifies potential applicants of the application review restrictions and that companies are aware of the process. The program has created new panels, including one for device, diagnostics, and new technologies, to accommodate so many preliminary applications.

Mr. Roberts explained that available funds are a problem. By Oversight Committee direction, the program is now getting more quality applications going through the peer review process. The

program plans to focus on outreach to family foundations and other funds to invest in biotechnology research.

Dr. Smith discussed the release of FY 2024 requests for applications, and the number of preliminary applications received since the opening of the applications. The total request from the applications submitted at this point is over a quarter of a billion dollars. He indicated that the program would like to see more devices, diagnostic and new technology applications.

An Oversight committee member asked Dr. Smith about the company relocating from Washington. Dr. Smith responded that he would provide the company's proposed relocation plan to the committee member.

In response to a member's question about another recommended company, Dr. Smith clarified that CPRIT will fund projects that are cancer-related, such as ancillary therapeutics addressing side effects of cancer treatments. He explained that this is a longstanding policy of CPRIT, noting that this was the second award for the company.

Another Oversight committee member inquired whether CPRIT recoups funding through equity. Ms. Doyle mentioned that we have standard revenue sharing terms that are royalty-based no matter the indication.

An Oversight Committee member asked whether CPRIT will offer the relocation RFA in the future. Dr. Smith explained that any product development RFA could be a relocation award because the company may apply from outside of Texas, but must relocate to Texas to receive the award. Ms. Doyle added that CPRIT renamed the relocation RFA because prospective applicants did not understand that CPRIT does not pay for relocation costs.

Compliance Certification

Presiding Officer Dr. Patel reminded members that Mr. Burgess previously certified compliance of the process for product development awards.

Conflict of Interest Notification

Presiding Officer Dr. Patel noted for the record that no Oversight Committee member reported a conflict of interest with any award recommendation presented today.

Approval Process – Product Development Awards

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Montgomery, the Oversight Committee members voted unanimously to approve the PIC's six recommendations for product development awards.

MOTION:

On a motion made by Mr. Margo and seconded by Mr. Montgomery, the Oversight Committee members voted unanimously to approve the delegation of contract negotiation authority to CPRIT's CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

MOTION:

On a motion made by Mr. Margo and seconded by Mr. Montgomery, the Oversight Committee members voted unanimously to approve the authorization of CPRIT to disburse grant funds via advance payments upon execution of the award contract and the successful completion of tranches to the six companies approved for awards today.

Scientific Research and Prevention Program Committee Appointments – Agenda Item 11, Tab 8

Mr. Roberts presented his appointments to the CPRIT's Scientific Research and Prevention Programs Committee:

- Nathanael S. Gray, Ph.D.
- Lourdes Baezconde-Garbanati, Ph.D., M.P.H.
- Erin Kobetz, Ph.D.
- Isabel Scarinci, Ph.D.
- Melissa Troester, Ph.D.
- Tristan Sissung, Ph.D.
- Felicitas L. Lacbawan, M.D.

MOTION:

On a motion by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee voted unanimously to approve the CEO's seven appointments to the Scientific Research and Prevention Program Committee.

Advisory Committees – Item 12, Tab 9

Presiding Officer Dr. Patel recognized Mr. Roberts to present the Presiding Officer's new appointments to the advisory committees.

Mr. Roberts presented Dr. Pavan Reddy's appointment to the Clinical Trials Advisory Committee and Laura Wood's appointment to the Prevention Advisory Committee.

He also noted the three new appointments to the University Advisory Committee.

MOTION:

On a motion made by Dr. Cummings and seconded by Mr. Montgomery, the Oversight Committee voted unanimously to approve the two advisory committee appointments.

University Advisory Committee Presentation:

Presiding Officer Dr. Patel called on Dr. Le Beau to introduce Dr. Peter Davies, Chair of the University Advisory Committee (UAC), to provide the UAC 2023 Annual Report.

Dr. Le Beau introduced Dr. Davies.

Dr. Davies presented the UAC 2023 Annual Report.

Oversight Committee members thanked Dr. Davies for his leadership on the University Advisory Committee.

In response to a question by an Oversight Committee member inquiring if there are any data on follow-up success on CPRIT grants, Dr. Davies clarified that Dr. Le Beau might know, but the information would help develop a comprehensive picture of the academic research program. Dr. Le Beau added that CPRIT has the data and can share it.

Another Oversight Committee asked about communicating the results of CPRIT grantee work and prioritizing CPRIT accomplishments on a national stage. Dr. Davies responded that the CPRIT program is nationally recognized. Dr. Le Beau added that groups from other states have approached CPRIT seeking to replicate what Texas is doing.

Presiding Officer Dr. Patel noted that he has attended UAC meetings and they are rigorous and to the point on how they can help CPRIT. He and the other Oversight Committee members thanked Dr. Davies for the presentation.

Chief Operating Officer Report – Agenda Item 14, Tab 11

Taking up Agenda Item 14 out of order, Presiding Officer Dr. Patel recognized Chief Operating Officer Heidi McConnell to present her report.

Ms. McConnell presented her report on the operating budget, performance measures, and debt issuance history. She said that, in the second quarter, the Texas Public Finance Authority issued \$66 million in commercial paper notes on CPRIT's behalf. By the end of this fiscal year, \$298.3 million in bond proceeds will be issued.

Ms. McConnell also updated the members on the upcoming CPRIT conference.

There were no questions for Ms. McConnell.

Fiscal Year 2024 Bond Issuance Resolution – Agenda Item 15, Tab 12

Presiding Officer Dr. Patel recognized Ms. McConnell to introduce the FY 2024 bond issuance resolution.

She presented the annual request seeking the Texas Public Finance Authority to issue debt on behalf of CPRIT in an amount not to exceed \$300 million in FY 2024. Ms. McConnell projects \$298.4 million in commercial paper notes over four separate issuances, and that bond proceeds will pay for grant costs associated with projects approved from FY 2016 to the present.

There were no questions for Ms. McConnell.

MOTION:

On a motion by Mr. Margo and seconded by Mr. Montgomery, the Oversight Committee voted unanimously to approve the resolution requesting financing for \$300 million in bond proceeds by the Texas Public Finance Authority in FY 2024.

Contract Approval – Grant Management Services – Agenda Item 16, Tab 13

Presiding Officer Dr. Patel recognized Ms. McConnell to present the staff's recommendation regarding the grant management services contract. She explained that staff recommended exercising the second renewal option with General Dynamics Information Technology (GDIT) for \$9,662,900 in FY 2024. The renewal includes an annual payment of \$1.1 million for subscription to the grant management platform and an estimated \$8,562,900 in time and materials expended by GDIT on labor and direct costs for grant application receipt, peer review meeting support, and post award grant management support.

There were no questions for Ms. McConnell.

MOTION:

On a motion by Mr. Margo and seconded by Mr. Montgomery, the Oversight Committee voted unanimously to approve the grant management support services contract renewal with General Dynamics Information Technology for an amount not to exceed \$9,662,900.

Amendments to 25 T.A.C. Chapters 701 and 703 – Agenda Item 13, Tab 10

Presiding Officer Dr. Patel recognized assistant general counsel Cameron Eckel to present the proposed rule amendments. Ms. Eckel reviewed the proposed changes, located behind Tab 10. All changes relate to the use of the term "Scope of Work." A final vote on the proposed changes will take place at the August Oversight Committee meeting.

MOTION:

On a motion by Mr. Montgomery and seconded by Dr. Rice, the Oversight Committee voted unanimously to approve the publication of the proposed changes to Chapters 701 and 703 in the *Texas Register*.

Advisory Committees – Item 12, Tab 9

Product Development Advisory Committee Presentation:

Returning to Agenda Item 12, Presiding Officer Dr. Patel called on Dr. Smith to introduce the Product Development Advisory Committee co-chairs, Mr. Andrew Strong and Dr. Michele Park.

Following the Product Development Advisory Committee's presentation, an Oversight Committee member asked if CPRIT has made an impact in the early oncology investment market, since investments are traditionally on the east and west coasts. Dr. Park confirmed that the investment community was aware of CPRIT.

Mr. Strong commended the Oversight Committee for fully committing the PDR funds for FY 2022 and FY 2023. He reported that applicants now know they must not wait to submit their applications, that there is urgency to be one of the 15 applications presenting to the peer review panels. Mr. Strong expressed concerns regarding timing, noting that the program changes were supposed to shorten the timing to funding to three months, but that CPRIT pushed the FY 2023 award announcement from the February meeting to the May meeting.

Mr. Strong addressed a question that an Oversight Committee member asked earlier in the meeting. He explained that companies are not padding or inflating their budgets. Companies know that there are limited funds, and that they must defend their budgets. He strongly supported the budget negotiations that took place for FY 2023 Cycle 1. However, he noted his concerns about the timeline for review and negotiation of the budgets.

He suggested that the program handle the rush to apply by reviewing like venture capitalists, focusing on applications that are in the "sweet spot," meaning those companies that can raise matching funds. Mr. Strong proposed that there could be "dry powder" follow on funds for companies that CPRIT has previously funded, such as reinvesting in companies that are homegrown from a Texas academic institution. Mr. Strong also recommended capping the funding amount per award and continuing budget negotiations moving forward.

An Oversight Committee member and Mr. Strong discussed the potential for PDAC members serving as mentors/advisors for awarded companies.

Communication Report – Agenda Item 17, Tab 14

Presiding Officer Dr. Patel recognized Communications Director Mark Loeffler to present his report. Mr. Loeffler updated the committee members on communications activities.

There were no questions for Mr. Loeffler.

Subcommittee Business – Agenda Item 18

Presiding Officer Dr. Patel informed the Oversight Committee members of the upcoming election of new officers in August as well new subcommittee assignments.

Internal Auditor Report – Agenda Item 10, Tab 7

Returning to Agenda Item 10, Presiding Officer Dr. Patel recognized Daniel Graves to present the internal auditor report. Mr. Graves updated the committee members on the FY 2023 Internal Audit Plan schedule. He directed the members to page 7-3 of the meeting book with the list of audits and audit advisory engagements, explaining that Weaver completed the contract risk

management assessment and was currently executing the post-award compliance program, purchasing, and IT general controls engagements.

In response to a question by an Oversight Committee member inquiring if it is the compliance program's responsibility to follow up on the contract risk assessment, Mr. Graves responded that CPRIT's management is responsible for assigning follow up activities.

MOTION:

On a motion by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee voted unanimously to approve the Contract Risk Assessment Model Advisory Audit Report.

Presiding Officer Dr. Patel announced the committee would go into closed session at 12:12 p.m. pursuant to Texas Government Code 551.076 to receive an update on the Internal Audit Report over Information Technology General Controls. He asked for Mr. Roberts, Ms. Doyle, Ms. McConnell, Mr. Burgess, Ms. Eckel, Shannon Cusick, Soma Emenike and Mr. Graves to join the members in closed session.

The Board reconvened in open session at 1:01 p.m.

Presiding Officer Dr. Patel stated that the Oversight Committee would not take up standing items 19 and 20.

Future Meeting Dates and Agenda Items – Agenda Item 21


Presiding Officer Dr. Patel reminded members that the CPRIT Oversight Committee will meet on August 16.

Adjournment – Agenda Item 22


MOTION:

There being no further business, the Oversight Committee voted unanimously to approve Presiding Chair Dr. Patel's motion to adjourn, which Mr. Montgomery seconded.

The meeting adjourned at 1:01 p.m.



Signature



Date



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

May 5, 2023

Dear Oversight Committee Members:

I am pleased to present the Program Integration Committee's (PIC) unanimous recommendation for funding nine grant applications totaling \$73,081,927. The PIC recommendations for three academic research and six product development research grant awards are attached.

Dr. Michelle Le Beau, CPRIT's Chief Scientific Officer, and Dr. Ken Smith, CPRIT's Chief Product Development Officer, have prepared overviews of the recommended academic research and product development research slates to assist your evaluation of the recommended awards. The overviews are intended to provide a comprehensive summary with enough detail to understand the substance of the proposal and the reasons endorsing grant funding. In addition to the full overviews, all the information considered by each Review Council is available by clicking on the appropriate link in the portal. This information includes the application, peer reviewer critiques, and the CEO affidavit for each proposal.

The approval of these grant recommendations is governed by a statutory process that requires two-thirds of the members present and voting to approve each recommendation. Vince Burgess, CPRIT's Chief Compliance Officer, will certify that the review process for the recommended grants followed CPRIT's award process prior to any Oversight Committee action.

The award recommendations will not be considered final until the Oversight Committee meeting on May 17, 2023. Consistent with the non-disclosure agreement that all Oversight Committee members have signed, the recommendations should be kept confidential and not be disclosed to anyone until the award list is publicly announced at the Oversight Committee meeting. I request that Oversight Committee members not print, email, or save to your computer's hard drive any material on the portal. I appreciate your assistance in taking all necessary precautions to protect this information.

If you have any questions or would like more information on the review process or any of the projects recommended for an award, CPRIT's staff, including myself, Dr. Le Beau, and Dr. Smith are always available. Please feel free to contact us directly should you have any questions. The programs that will be supported by the CPRIT awards are an important step in our efforts to mitigate the effects of cancer in Texas.

Thank you for being part of this endeavor.

Sincerely,
Wayne R. Roberts,
Chief Executive Officer

WD
Cindy Barberistays
5/17/2023

WP
Cindy Barbero
Payne
5/17/2023

ACADEMIC RESEARCH GRANT AWARD RECOMMENDATIONS

The PIC unanimously recommends approval of three academic research recruitment grant proposals totaling \$14,000,000. The recommended grant proposals were submitted in response to the following grant mechanisms: *Recruitment of Established Investigators*; and *Recruitment of First-Time, Tenure-Track Faculty Members*.

The Scientific Review Council (SRC) provided the prioritized list of four recommendations for grant awards to the presiding officers on April 14, 2023. Prior to the PIC meeting, one of the recommended applications was withdrawn by the applicant; therefore, the PIC considered three recruitment recommendations at its May 3 meeting.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these academic research proposals met the following CPRIT funding priorities:

- Could lead to immediate or long-term medical and scientific breakthroughs in the area of Cancer Prevention or cures for cancer;
- Strengthen and enhance fundamental science in Cancer Research;
- Ensure a comprehensive coordinated approach to Cancer Research and Cancer Prevention;
- Address federal or other major research sponsors' priorities in emerging scientific or Technology fields in the area of Cancer Prevention, or cures for cancer
- Have a demonstrable economic development benefit to this state;
- Enhance research superiority at institutions of higher education in this state by creating new research superiority, attracting existing research superiority from institutions not located in this state and other research entities, or enhancing existing research superiority by attracting from outside this state additional researchers and resources; and
- Address the goals of the Texas Cancer Plan.

Academic Research Recruitment Award Recommendations Cycle 23.4						
<i>REI: Recruitment of Established Investigators</i>						
<i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>						
Rank	App. ID	Mechanism	Candidate	Organization	Budget	Final Score
1	RR230031	RFTFM	Dian Yang, Ph.D.	The University of Texas Southwestern Medical Center	\$2,000,000	1.0

Academic Research Recruitment Award Recommendations						
Cycle 23.4						
<i>REI: Recruitment of Established Investigators</i>						
<i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>						
Rank	App. ID	Mechanism	Candidate	Organization	Budget	Final Score
2	RR230032	REI	Yuan Zhu, M.D.	The University of Texas Southwestern Medical Center	\$6,000,000	1.8
3	RR230029	REI	Michael King, Ph.D.	Rice University	\$6,000,000	2.0

PRODUCT DEVELOPMENT RESEARCH GRANT AWARD RECOMMENDATIONS

The PIC unanimously recommends approval of six product development research grant proposals totaling \$59,081,927. The recommended grant proposals were submitted in response to the following grant mechanisms: *SEED Awards for Product Development Research*; *Texas New Technologies Company Awards for Product Development Research*; and *Texas Therapeutics Company Awards for Product Development Research*.

The Product Development Review Council (PDRC) provided the prioritized list of recommendations to the presiding officers on January 30, 2023. The PIC deferred the six recommended awards at its February 1 meeting to allow time for the Chief Product Development Officer to negotiate budget reductions with each of the six companies. I notified the Oversight Committee on February 6, 2023, that pursuant to Texas Administrative Code § 702.19(e) I granted Dr. Smith a waiver from the general prohibition against communicating to allow him to conduct the budget negotiations. The PIC unanimously recommended the previously deferred applications with revised budgets at its May 3 meeting.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these product development research proposals met the following CPRIT funding priorities:

- Could lead to immediate or long-term medical and scientific breakthroughs in the area of Cancer Prevention or cures for cancer;
- Ensure a comprehensive coordinated approach to cancer research;
- Are interdisciplinary or interinstitutional;
- Address federal or other major research sponsors' priorities in emerging scientific or Technology fields in the area of Cancer Prevention, or cures for cancer;

- Are matched with funds available by a private or nonprofit entity and institution or institutions of higher education;
- Are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state;
- Have a demonstrable economic development benefit to this state;
- Expedite innovation and commercialization, attract, create, or expand private sector entities that will drive a substantial increase in high-quality jobs, and increase higher education applied science or Technology research capabilities; and
- Address the goals of the Texas Cancer Plan

Product Development Research Award Recommendations Cycle 23.1 <i>SEED: SEED Awards for Product Development Research</i> <i>TNTC: Texas New Technologies Company Awards for Product Development Research</i> <i>TTC: Texas Therapeutics Company Awards for Product Development Research</i>							
Rank	App. ID	Mechanism	Application Title	PI	Organization	Budget	Final Score
1	DP230079	TNTC	Building Differentiated Cell Therapy Manufacturing Technologies to Attract Value-Added Biotech Partnerships	Bock, Jason	Resilience Texas LLC dba CTMC	\$9,100,000	2.3
2	DP230062	TTC	7HP349, a Small Molecule, Oral Integrin Activator to Treat Patients With anti-P0-1 Resistant Melanoma	Lewis, Lionel D	7 Hills Pharma LLC	\$13,439,001	2.6

Product Development Research Award Recommendations Cycle 23.1 <i>SEED: SEED Awards for Product Development Research</i> <i>TNTC: Texas New Technologies Company Awards for Product Development Research</i> <i>TTC: Texas Therapeutics Company Awards for Product Development Research</i>							
Rank	App. ID	Mechanism	Application Title	PI	Organization	Budget	Final Score
3	DP230064	SEED	IND-Enabling Studies of ONP-001: A Nano-Codelivery Formulation with Two Drugs of Distinct Mechanisms of Action for Treating Pancreatic Ductal Adenocarcinoma	Ma, Guorong	OmniNano Pharmaceuticals LLC	\$2,711,437	3.3
4	DP230076	TTC	OncoResponse OR502 anti-LILRB2 monoclonal antibody Phase 1-2 clinical study	Stocks, Clifford J	OncoResponse	\$13,259,174	3.6
5	DP230066	TTC	Improving Cancer Patient Outcomes by Activating Lung Innate Immunity	Scott, Brenton	Pulmotect, Inc.	\$8,851,165	3.3
6	DP230071	TTC	Clinical development of a novel CD127 antibody for treating patients with relapsed/refractory Acute Lymphoblastic Leukemia (ALL)	Varadhachary, Atul	Allterum Therapeutics, LLC	\$11,721,150	2.6